Eli Lilly and Co. stock gains on trillion-dollar valuation and fresh FDA approval

Eli Lilly and Co. stock (ISIN US5324571083) is trading near a record valuation, with the company’s market capitalization recently crossing USD 1,000,000,000,000 as of September 18, 2026 and the shares changing hands around USD 1,155 on the New York Stock Exchange.

FDA approval and trillion-dollar valuation

According to Economic Times Pharma on September 19, 2026, Eli Lilly received full U.S. Food and Drug Administration approval for a breast cancer drug combination based on Inluriyo together with an existing therapy, strengthening its oncology franchise.

This regulatory success adds to the momentum from the obesity-franchise pipeline. As Yahoo Finance reported on September 18, 2026, Eli Lilly plans to present mid-stage data for its eloraTZP two-drug obesity combination at a European Association for the Study of Diabetes symposium on September 30, 2026, with the stock trading near USD 1,152 and a market capitalization around USD 1.01 trillion as investors bet on sustained weight-loss demand.

Per Economic Times on September 19, 2026, Eli Lilly’s share price has risen about 300 percent over a little more than four years since its first GLP-1 drug was approved, lifting the company above USD 1 trillion in market value and making it the world’s most valuable pharmaceutical company.

Price action, range and valuation metrics

On September 18, 2026, real-time data from Nasdaq via CNBC showed Eli Lilly stock last trading at USD 1,155.30, up 0.25 percent from the prior close of USD 1,152.44, with an intraday high of USD 1,157.60 and a low of USD 1,140.27.

The same overview indicated a 52-week range between USD 712.05 and USD 1,292.65 as of August 19, 2026, placing the current price roughly USD 143 below the 52-week high and more than USD 443 above the 52-week low, illustrating how far the stock has run over the past year while still trading below its recent peak.

In valuation terms, Yahoo Finance noted that Eli Lilly trades at a forward price-to-earnings multiple of about 24 times, down from a trailing multiple of around 38 times, while carrying a market capitalization near USD 1.01 trillion as of September 18, 2026, reflecting lofty expectations but also some compression as earnings catch up to the share price.

Analyst upgrades and price targets

The recent rally has been reinforced by fresh analyst support. According to TipRanks on September 18, 2026, Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Eli Lilly, setting a price target of USD 1,284 per share, compared with the closing price of USD 1,152.44 the previous trading day, implying upside of roughly USD 131 or about 11.4 percent from that level.

In the same report, TipRanks highlighted that Berenberg Bank upgraded Eli Lilly stock from Hold to Buy on September 14, 2026, lifting its price target to USD 1,400, which represents approximately 21.5 percent potential upside versus the USD 1,152.44 share price referenced in the analysis.

The same analyst overview noted that the Street’s consensus for Eli Lilly stands at a Strong Buy rating with an average price target around USD 1,382.63, implying about 20.2 percent upside from current levels, underscoring how many houses expect the company’s growth in obesity and oncology to sustain the trillion-dollar valuation.

Per an article cited by Ground News on September 19, 2026, Berenberg’s Kerry Holford argued that Eli Lilly delivers sales growth through to 2030 significantly ahead of peers and highlighted what she called best-in-class research and development productivity as justification for her USD 1,400 price target, which implies around 21 percent upside from Thursday’s close when the report was published.

Fundamentals, pipeline and risk factors

Recent analyses emphasize that Eli Lilly’s fundamentals are tightly linked to its obesity and diabetes franchise. As 24/7 Wall St wrote on September 18, 2026, the upcoming September 30 data release for eloraTZP, which combines eloralintide with tirzepatide, is seen as a critical test of whether Lilly can deepen weight-loss efficacy beyond its already approved GLP-1-based therapies and thus sustain revenue growth consistent with a trillion-dollar market cap.

That analysis pointed out that options markets have turned cautious ahead of the readout, with put-call ratios above 4.6 for certain October expiries, indicating that some investors are hedging in case the mid-stage results fail to meet high expectations, a reminder that pipeline risk remains even for a company with a strong track record.

From a broader profitability perspective, Yahoo Finance noted that Eli Lilly’s forward earnings multiple of about 24 times compares with a trailing multiple of around 38 times, suggesting that expected profit growth is gradually making the valuation less extreme even as the share price hovers only modestly below its 52-week high.

In addition to growth, some observers flag valuation and competition as key risks. The same 24/7 Wall St piece pointed to headwinds faced by Novo Nordisk’s GLP-1 franchise and emerging competition from Viking Therapeutics, arguing that a truly convincing eloraTZP win could raise the bar for rivals but that any disappointment might prompt investors to question the premium embedded in Eli Lilly’s share price.

Next events and investor takeaway

The next major catalyst for Eli Lilly stock is the mid-stage eloraTZP data presentation scheduled for September 30, 2026 at a European Association for the Study of Diabetes meeting, as referenced by Yahoo Finance, with investors watching closely to see whether the two-drug combination can deliver superior weight loss versus tirzepatide alone.

According to the event section on CNBC, the next estimated earnings date for Eli Lilly is October 29, 2026, while the most recent ex-dividend date was August 14, 2026 with a dividend amount of USD 1.73 per share, giving income-focused investors a timeline for the next set of quarterly figures.

For now, the combination of a USD 1 trillion market capitalization, a share price near USD 1,155 as of September 18, 2026 and analyst targets stretching as high as USD 1,400 suggests that the market is willing to pay a premium for Eli Lilly stock as long as its obesity and oncology pipelines continue to deliver, but options positioning and competitive pressure underline that execution on upcoming data is crucial.

More news and analyses on Eli Lilly and Co. stock